News | January 20, 2026
Syngene locks in Bristol Myers Squibb alliance through 2035
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
The Eugene facility, with more than 20 years of history, houses a 16,000-square-foot R&D lab and a newly constructed 30,000-square-foot manufacturing facility
The company is rolling out ARTEMIS, a next-generation AI platform for capsid design
Developed using STEERLife’s proprietary FragMelt continuous processing platform, the approval marks a major breakthrough in pharmaceutical manufacturing
Dr. Reddy’s Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% is an antihistamine eye drop, indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander
CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
Heart failure affects an estimated 64.3 million people worldwide
The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates
Applications include detailed scientific rationale and supporting clinical evidence
Subscribe To Our Newsletter & Stay Updated
